Literature DB >> 16313339

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.

Sakae Tanaka1, Kozo Nakamura, Naoyuki Takahasi, Tatsuo Suda.   

Abstract

Osteoclasts are primary cells for physiological and pathological bone resorption, and receptor activator of nuclear factor-kappaB ligand (RANKL) is critically involved in the differentiation, activation, and survival of these cells. Recently, therapeutics for pathological bone destruction targeting RANKL pathways has attracted a great deal of attention. Herein, we review the recent advances in the research on osteoclast biology and discuss the advantages and disadvantages of anti-RANKL therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16313339     DOI: 10.1111/j.0105-2896.2005.00327.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  102 in total

1.  A microRNA expression signature of osteoclastogenesis.

Authors:  Toshifumi Sugatani; Jean Vacher; Keith A Hruska
Journal:  Blood       Date:  2011-01-27       Impact factor: 22.113

Review 2.  MicroRNAs and their roles in osteoclast differentiation.

Authors:  Zhuying Xia; Chao Chen; Peng Chen; Hui Xie; Xianghang Luo
Journal:  Front Med       Date:  2011-12-27       Impact factor: 4.592

3.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

4.  Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

Authors:  Francescaromana Festuccia; Maryam Tayefeh Jafari; Alessandra Moioli; Claudia Fofi; Simona Barberi; Stefano Amendola; Salvatore Sciacchitano; Giorgio Punzo; Paolo Menè
Journal:  J Nephrol       Date:  2016-07-09       Impact factor: 3.902

5.  The paired-box homeodomain transcription factor Pax6 binds to the upstream region of the TRAP gene promoter and suppresses receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation.

Authors:  Masakazu Kogawa; Koji Hisatake; Gerald J Atkins; David M Findlay; Yuichiro Enoki; Tsuyoshi Sato; Peter C Gray; Yukiko Kanesaki-Yatsuka; Paul H Anderson; Seiki Wada; Naoki Kato; Aya Fukuda; Shigehiro Katayama; Masafumi Tsujimoto; Tetsuya Yoda; Tatsuo Suda; Yasushi Okazaki; Masahito Matsumoto
Journal:  J Biol Chem       Date:  2013-08-29       Impact factor: 5.157

Review 6.  Targeting polymer therapeutics to bone.

Authors:  Stewart A Low; Jindřich Kopeček
Journal:  Adv Drug Deliv Rev       Date:  2012-01-28       Impact factor: 15.470

7.  Mature and activated osteoclasts exist in the synovium of rapidly destructive coxarthrosis.

Authors:  Kenji Ogawa; Masaaki Mawatari; Mitsunori Komine; Masamori Shigematsu; Masaru Kitajima; Akiko Kukita; Takao Hotokebuchi
Journal:  J Bone Miner Metab       Date:  2007-10-25       Impact factor: 2.626

8.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo.

Authors:  Hyun-Ju Kim; Kaihua Zhang; Lihong Zhang; F Patrick Ross; Steven L Teitelbaum; Roberta Faccio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

9.  NF-kappaB2 (p100) limits TNF-alpha-induced osteoclastogenesis.

Authors:  Sakae Tanaka; Hiroyasu Nakano
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

10.  RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.

Authors:  Renee Bargman; Alice Huang; Adele L Boskey; Cathleen Raggio; Nancy Pleshko
Journal:  Connect Tissue Res       Date:  2010-04       Impact factor: 3.417

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.